Traditional workflows continue to prioritise binding over functional relevance — often leading to the advancement of non-functional candidates and the loss of those with true therapeutic potential.
And while binding is essential, it’s not a reliable predictor of therapeutic effectiveness. A binding antibody might not block a signalling pathway, trigger a desired immune response, or internalise into a cell, all of which are key mechanisms of action for therapeutic success.
Field Application Team Leader Jonathan Didier explains how the Envisia platform's function-focused approach can streamline the antibody development pipeline.
